Tykerb Overdosage

There is no specific antidote for the inhibition of EGFR (ErbB1) and/or HER2/neu (ErbB2) tyrosine phosphorylation. The maximum oral dose of lapatinib (Tykerb) in clinical trials was 1800 mg once daily.
Taking lapatinib (Tykerb) more frequently than recommended could result in serum concentrations exceeding those observed in clinical trials; therefore, missed doses should not be replaced, and dosing should resume with the next scheduled daily dose (see Dosage & Administration).
Asymptomatic and symptomatic cases of overdose have been reported with lapatinib (Tykerb). Symptoms observed include known lapatinib (Tykerb) associated events (see Adverse Reactions) and in some cases sore scalp, sinus tachycardia (with otherwise normal ECG) and/or mucosal inflammation.
Lapatinib (Tykerb) is not significantly renally excreted and is highly bound to plasma proteins; therefore, hemodialysis is not expected to enhance lapatinib elimination.
Further management should be as clinically indicated or as recommended by the national poisons center, where available.